Background: Rheumatoid arthritis (RA) is an immune mediated joint-based chronic inflammatory
disorder recognized by joint inflammation, destruction, pain and remission. Currently, numerous pharmacotherapeutic
strategies have gained immense popularity in RA therapy and improving the patient life.
Methods: Besides, it exhibits numerous drawbacks such as requirement of high dose of drugs, unavoidable
adverse effects and diseases remission. Thus, use of currently available pharmacotherapeutics employing
conventional formulations can only provide therapeutic effects to a certain extent.
Results: Recent advancements in nanotechnology-based lipidic vesicular nanocarriers have led provided improved
efficacy and safety for the anti-rheumatic drugs. These include liposomes, stealth liposomes, ethosomes,
transfersomes, etc., which have shown their potential to improve the therapeutic efficacy of antirheumatic
drugs with lesser toxicity. Although the results of animal models for use of lipid vesicular nanocarriers
for drug targeting in RA have been found to be highly promising, but lack of sufficient data in a clinical
setup are still evident to demonstrate their practical utility in patient populations. In this regard, considerable
research studies are required for evaluating the efficacy and safety of the aforementioned nanocarriers in RA
through clinical studies.
Conclusion: The present review, therefore, covers the brief pathophysiology of RA, current medication and
their challenges in RA therapy. Besides, an extensive account on recent advancements in novel lipid vesicular
nanocarriers in RA therapy has also been addressed with special emphasis on the patent literature too.